A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers

Trial Profile

A clinical study to evaluate the biological effects of pre-operative intravenous administration of JX-594 (thymidine kinase-deactivated Vaccinia virus plus GM-CSF) prior to planned surgical resection of locally advanced/poor prognosis or metastatic cancers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 May 2018

At a glance

  • Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pexastimogene devacirepvec (Primary)
  • Indications Bladder cancer; Liver cancer; Malignant melanoma; Renal cell carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms Pre-Operative-JX594
  • Most Recent Events

    • 17 May 2018 According to a Transgene media release, data from this study will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting.
    • 21 Mar 2018 Status changed from recruiting to active, no longer recruiting, according to a Transgene media release.
    • 28 Jan 2016 Status changed from suspended to recruiting as per United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top